NF1 and neoplasm: However, the absence of germline sequencing in our study impedes definitive conclusions on the origin of inactivating variants in tumor suppressive genes such as CDKN2A or NF1. Recurrent mutations demonstrated a prominence of MAPK pathway activation, primarily through NRAS and BRAF activation, confirming previous reports [24,35].